Amedisys, Inc. (AMED)
Automate Your Wheel Strategy on AMED
With Tiblio's Option Bot, you can configure your own wheel strategy including AMED - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AMED
- Rev/Share 72.3231
- Book/Share 37.9677
- PB 2.6642
- Debt/Equity 0.3775
- CurrentRatio 1.2885
- ROIC 0.0494
- MktCap 3198598216.0
- FreeCF/Share 6.6855
- PFCF 14.5896
- PE 27.9391
- Debt/Assets 0.2073
- DivYield 0
- ROE 0.0993
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Here's Why You Should Retain AMED Stock in Your Portfolio for Now
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Amedisys' high Quality of Patient Care and Patient Satisfaction star ratings bring optimism to investors. Yet, a dull macroeconomic condition adds to the worry.
Read More
AMED or CHE: Which Is the Better Value Stock Right Now?
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (AMED) and Chemed (CHE). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Are Medical Stocks Lagging Amedisys (AMED) This Year?
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how Amedisys (AMED) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.
Read More
Why Is Amedisys (AMED) Up 1.3% Since Last Earnings Report?
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock?
Read More
Here's Why You Should Retain AMED Stock in Your Portfolio Now
Published: March 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Amedisys' high Quality of Patient Care and Patient Satisfaction star ratings bring optimism to investors. Yet, a dull macroeconomic condition adds to the worry.
Read More
Amedisys (AMED) Reports Q4 Earnings: What Key Metrics Have to Say
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Amedisys (AMED) Lags Q4 Earnings and Revenue Estimates
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Negative
Amedisys (AMED) came out with quarterly earnings of $0.96 per share, missing the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $0.94 per share a year ago.
Read More
Amedisys Reports Fourth Quarter and Year End 2024 Financial Results
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
BATON ROUGE, La., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2024.
Read More
About Amedisys, Inc. (AMED)
- IPO Date 1994-08-17
- Website https://www.amedisys.com
- Industry Medical - Care Facilities
- CEO Mr. Richard M. Ashworth
- Employees 19000